In April 2025, the "9th National Digestive Psychosomatic Academic Conference and Digestive Psychosomatic Alliance Academic Annual Meeting" was grandly held in Shanghai. As one of the most influential academic events in the field of digestive psychosomatic medicine in China, this conference brought together experts, scholars and corporate representatives from all over the country to conduct in-depth discussions on topics such as clinical practice, diagnosis and treatment strategies for digestive psychosomatic diseases.

As a benchmark representative of Taiwanese pharmaceutical companies, Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd. (hereinafter referred to as "Suzhou Chung-Hwa Chemical & Pharmaceutical") attended the conference with its core product Libofei^® calcium polycarbophil and other innovative drugs in the digestive field, and held a "Special Meeting on Calcium Polycarbophil - Diagnosis and Treatment Dilemmas and Countermeasures for IBS-C and FC", demonstrating its technical strength and industry responsibility in the treatment of digestive system diseases, and injecting new impetus into the promotion of the "Healthy China" and "Healthy Spleen and Stomach" undertakings.

Academic Feast: "New Thinking, New Technology" and "Integration of Chinese and Western Medicine" in the Diagnosis and Treatment of Digestive Psychosomatic Diseases

As an annual academic "feast", the National Digestive Psychosomatic Academic Conference focuses on presenting the annual basic and clinical innovation breakthroughs, showcasing academic development trends, practical medication experience, and academic thought debates, and predicts market prospects.

This conference deeply discussed the pathogenesis and clinical practice of digestive psychosomatic diseases, focusing on the precise and rational application of intestinal targeted neuromodulators, sharing of clinical experience, and academic innovation. It proposed the use of neuromodulators in digestive psychosomatic diseases (functional gastrointestinal diseases, gut-brain interaction disorders). Unlike psychiatric diseases, the intestinal targeting and gastroenterology diagnostic system should be firmly grasped to explain the application specifications of various central nervous system drugs.

The meeting also focused on rare gastrointestinal diseases, new technologies in gastrointestinal endoscopy, and the integration of Chinese and Western medicine theory and practice. Through consensus interpretation and debate, new consensus opinions were brewed.

Academic practice of Suzhou Chung-Hwa Chemical & Pharmaceutical: from product innovation to clinical value enhancement

As a Taiwanese pharmaceutical company rooted in the mainland for more than 30 years, Suzhou Chung-Hwa Chemical & Pharmaceutical became the focus of attention at the conference with its full-chain innovation capabilities in "R&D-production-clinical".

In the "Special Meeting on Calcium Polycarbophil - Diagnostic and Treatment Dilemmas and Countermeasures for IBS-C and FC", Professor Chen Shengliang of Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine mentioned that IBS-C and FC should rationally choose laxatives, such as the representative of bulk laxatives - calcium polycarbophil.

This drug is a bulk laxative. Its main ingredient, calcium polycarbophil, is decalcified under the action of gastric acid to form polycarbophil. Polycarbophil absorbs water and swells in the intestine to form a hydrophilic gel, which increases the water content and volume of the stool, making the stool fluffy, soft, and easy to excrete, thereby effectively relieving various constipation symptoms, such as constipation caused by irritable bowel syndrome, functional constipation, constipation caused by benign anal diseases, constipation in postoperative patients, etc. It is safe and effective for long-term use.

Data show that calcium polycarbophil is not absorbed into the blood and works directly in the intestines, making it safe and effective in treating constipation.

Literature indicates that appropriate oral dosage forms can improve medication compliance in patients with dysphagia. Calcium polycarbophil granules can improve patient compliance and reduce the risk of clinical medication, making it a preferred choice for the elderly and patients with dysphagia.

Professor Chen Shengliang also shared his special topic titled "Multi-dimensional Advantages and Clinical Practice Strategies of Calcium Polycarbophil in Treating Constipation". Professor Chen mentioned that the volume of the gel formed by calcium polycarbophil absorbing water and swelling increases, which mechanically stimulates the intestinal wall, promotes intestinal peristalsis, shortens colon transit time, significantly improves constipation symptoms, and improves patients' quality of life and treatment satisfaction.

Calcium polycarbophil can enhance the absorption of beneficial metabolites in the intestine, help improve intestinal barrier function, reduce the absorption of harmful substances, relieve intestinal inflammation, and promote intestinal peristalsis and defecation function.

Calcium polycarbophil can increase the abundance of beneficial intestinal bacteria, thereby improving constipation symptoms, enhancing intestinal immune function, improving the body's resistance to pathogens, and achieving comprehensive health management.

Regarding the use of drugs for constipation in special populations, Professor Chen mentioned that for pregnant women with constipation, calcium polycarbophil can relieve constipation and reduce complications such as hemorrhoids. Diabetic patients are prone to constipation due to nerve and vascular diseases. Calcium polycarbophil is safe to use in diabetic patients, does not affect blood sugar control, and has no obvious adverse reactions. It is an ideal choice for treating constipation.

The elderly have declining physical functions and fragile cardiovascular systems. Calcium polycarbophil can safely relieve constipation and improve the quality of life. In addition, for patients with postoperative intestinal paralysis, calcium polycarbophil can promote intestinal peristalsis and reduce postoperative constipation and abdominal distension.

Guideline recommendations can provide doctors with clear guidance on medication. The WGO guidelines list calcium polycarbophil as the first choice for long-term management of constipation (grade Ⅰ A); the ACG guidelines list calcium polycarbophil as the first-line medication for IBS-C (strongly recommended); and the JSGE guidelines position calcium polycarbophil as the core drug for constipation in the elderly. These guideline consensuses fully reflect the important clinical status of calcium polycarbophil in the management of chronic constipation.

Calcium polycarbophil has significant therapeutic effects and low average daily costs, making it cost-effective. It can reduce the financial pressure on patients and facilitate long-term use by patients.

Market Prospects Prediction: Opportunities and Challenges Driven by Policies

With the normalization of national centralized procurement and the promotion of the policy of revitalizing traditional Chinese medicine, the field of digestive and psychosomatic disease treatment has shown two major trends: one is the acceleration of evidence-based medical research on traditional Chinese medicine, and the other is that the consistency evaluation of generic drugs has become a "hard threshold" for market access. Suzhou Chung-Hwa Chemical & Pharmaceutical has successfully seized market share through the compliance layout of Libofei ^® polycarbophil calcium, such as passing the consistency evaluation.

The accelerated pace of modern life has led to a high incidence of functional gastrointestinal diseases, and patients' demand for safe and convenient medication is increasing.Libofei^® calcium polycarbophil has become the preferred solution for patients with chronic constipation due to its characteristics of "not being absorbed into the blood and being safe for long-term use". In addition, the oral care brand "Mi Ya Jie Ke" and the female health brand "He Le Kang" launched by the company for young people also reflect its strategic vision of extending from "disease treatment" to "big health" ecology.

The 9th National Digestive Mind and Body Academic Conference is not only a collision of academic ideas, but also a departure for industrial innovation. Suzhou Chung-Hwa Chemical & Pharmaceutical takes "passion, innovation, care, and health" as its core values, and provides scientific and personalized solutions for the treatment of digestive system diseases through technological breakthroughs, academic co-construction, and ecological extension. In the future, the company will continue to shoulder its industry responsibilities, drive development with innovation, and contribute more to the "Healthy China" strategy and the global pharmaceutical and health industry.